Hyperpolarized MRI, also known as hyperpolarized MRSI (or HP-MRSI), is a new technique representing a major development in molecular MR currently making the rounds in the international molecular imaging circuit.

Molecular imaging of psychiatric disorders has taken a few turns around the lab as a concept, and while some potential imaging methods, namely dopamine transport scanning, have shown some potential, the technique has not really taken off for psychiatric applications due to a mixed bag of results and a limited understanding of the pathophysiology.

First-order treatment of cancer typically involves chemo and/or radiation therapy and surgical intervention, but radionuclide therapies offer some advantages for select patients by delivering a very intense dose sequestered to affected tumor sites.

During the past five years, I have spent a considerable amount of time on the issue of supply of Tc-99m and its parent, Mo-99.

The first PET imaging study of its kind to show the viability of tumor angiogenesis imaging in humans with investigational Ga-68 NODAGA-Theranost has been conducted by researchers from the Theranostics Center for Molecular Radiotherapy and Molecular Imaging in Bad Berka, Germany, and other institutions including the National Cancer Institute and Advanced Imaging Projects based in Boca Raton, Fla. Molecular Imaging has obtained an exclusive sneak-peek at the study.

MRI-guided breast biopsy yielded high-risk lesions in 21.5 percent of cases, according to a study published in the September issue of the American Journal of Roentgenology.

Watch a presentation on nanoconstructs in cancer theranostics from the Methodist Hospital Research Institute and Tel Aviv University (TAU) posted online from the recent Summer School on Nanomedicine and Innovation.

Hyperscan is debuting at the 56th annual meeting of the American Society for Radiation Oncology (ASTRO), held September 14 – 16 in San Francisco.  Mevion representatives will formally introduce Hyperscan at booth 728 in the exhibit hall.